Diagonal Therapeutics

Biotech · Private

Agonist antibody therapeutics for disease treatment

diagonaltx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
16
1 granted · 15 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2225MOBIUS SCIENTIFIC INC.——
2226PMV Pharmaceuticals—$74M
2227FibroBiologics, LLC—$11M
2228Diagonal Therapeutics——
2229Nimbus Therapeutics——
2230Inflection Medicine——
2231Tenvie——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 16
  • Bispecific Agonistic Antibodies To Activin A Receptor Like Type 1 (ALK1)application
  • Bispecific Agonistic Antibodies To Activin A Receptor Like Type 1 (ALK1)granted
  • Heteromeric Agonistic Antibodies To IL-18 Receptorapplication
  • Bispecific Agonistic Antibodies To IL12 Receptorapplication
  • Bispecific Agonistic Antibodies To Activin A Receptor Like Type 1 (ALK1)application
  • Hinge-modified Bispecific Antibodiesapplication
  • Heteromeric Agonistic Antibodies To IL-18 Receptorapplication
  • Hinge-modified Bispecific Antibodiesapplication
  • Heteromeric Agonistic Antibodies To IL-18 Receptorapplication
  • Bispecific Agonistic Antibodies To IL12 Receptorapplication
  • Activin Receptor Type II A/b (actriia/b) Antibodiesapplication
  • De Novo Antibodies To Activin A Receptor Like Type 1 (ALK1)application

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.